Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03937479Phase 2Completed

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

Role: collaborator

NCT02767167Not ApplicableCompleted

Contribution of Cow's Milk to Iodine and Selenium Status in Women of Child-bearing Age

Role: collaborator

NCT01119300Phase 4Completed

EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin

Role: collaborator

NCT01119274Phase 4Completed

EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon

Role: collaborator

NCT01119261Phase 4Completed

EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol

Role: collaborator

All 5 trials loaded